Protocol No
WEILLCORNELL-AMY2006-DPD
Staff Member
Anita D'Souza
Phase
II
Summary
The purpose of this study is to assess the tolerability and safety of an investigational combination of drugs in relapsed/refractory AL amyloidosis.
Objective
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov